Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

Xueyan Zhang, Katsuyoshi Takata, Wei Cui, Tomoko Miyata-Takata, Yasuharu Sato, Mai Noujima-Harada, Tadashi Yoshino

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH gene subfamily member, in B-cell lymphoma 2 (BCL2)-positive and -negative FL, and evaluated its association with tumor cell proliferation in an FL-derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1-2 samples (19/20; 95%) and over half of grade 3A FL samples (5/9; 56%) were PCDHGA3-positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2-negative FL (13/15; 87%) and FL with diffuse area (10/10; 100%). The FL-derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.

Original languageEnglish
Pages (from-to)4622-4628
Number of pages7
JournalMolecular Medicine Reports
Volume14
Issue number5
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Follicular Lymphoma
Cell growth
B-Cell Lymphoma
Tumors
Genes
Growth
Neoplasms
Cells
Cell proliferation
Gene expression
Tumor Necrosis Factor Receptors
Up-Regulation
Cell Proliferation
Pseudolymphoma
Gene Knockdown Techniques
Gene Expression
Cell Line
Tumor Suppressor Genes
Molecular Biology
Maintenance

Keywords

  • Follicular lymphoma
  • Protocadherin A3
  • Tumor cell growth

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Oncology
  • Genetics
  • Cancer Research

Cite this

Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth. / Zhang, Xueyan; Takata, Katsuyoshi; Cui, Wei; Miyata-Takata, Tomoko; Sato, Yasuharu; Noujima-Harada, Mai; Yoshino, Tadashi.

In: Molecular Medicine Reports, Vol. 14, No. 5, 01.11.2016, p. 4622-4628.

Research output: Contribution to journalArticle

Zhang, Xueyan ; Takata, Katsuyoshi ; Cui, Wei ; Miyata-Takata, Tomoko ; Sato, Yasuharu ; Noujima-Harada, Mai ; Yoshino, Tadashi. / Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth. In: Molecular Medicine Reports. 2016 ; Vol. 14, No. 5. pp. 4622-4628.
@article{6b5ae61097a949e9a9c319749bca057e,
title = "Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth",
abstract = "Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH gene subfamily member, in B-cell lymphoma 2 (BCL2)-positive and -negative FL, and evaluated its association with tumor cell proliferation in an FL-derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1-2 samples (19/20; 95{\%}) and over half of grade 3A FL samples (5/9; 56{\%}) were PCDHGA3-positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2-negative FL (13/15; 87{\%}) and FL with diffuse area (10/10; 100{\%}). The FL-derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.",
keywords = "Follicular lymphoma, Protocadherin A3, Tumor cell growth",
author = "Xueyan Zhang and Katsuyoshi Takata and Wei Cui and Tomoko Miyata-Takata and Yasuharu Sato and Mai Noujima-Harada and Tadashi Yoshino",
year = "2016",
month = "11",
day = "1",
doi = "10.3892/mmr.2016.5808",
language = "English",
volume = "14",
pages = "4622--4628",
journal = "Molecular Medicine Reports",
issn = "1791-2997",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

AU - Zhang, Xueyan

AU - Takata, Katsuyoshi

AU - Cui, Wei

AU - Miyata-Takata, Tomoko

AU - Sato, Yasuharu

AU - Noujima-Harada, Mai

AU - Yoshino, Tadashi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH gene subfamily member, in B-cell lymphoma 2 (BCL2)-positive and -negative FL, and evaluated its association with tumor cell proliferation in an FL-derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1-2 samples (19/20; 95%) and over half of grade 3A FL samples (5/9; 56%) were PCDHGA3-positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2-negative FL (13/15; 87%) and FL with diffuse area (10/10; 100%). The FL-derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.

AB - Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH gene subfamily member, in B-cell lymphoma 2 (BCL2)-positive and -negative FL, and evaluated its association with tumor cell proliferation in an FL-derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1-2 samples (19/20; 95%) and over half of grade 3A FL samples (5/9; 56%) were PCDHGA3-positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2-negative FL (13/15; 87%) and FL with diffuse area (10/10; 100%). The FL-derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.

KW - Follicular lymphoma

KW - Protocadherin A3

KW - Tumor cell growth

UR - http://www.scopus.com/inward/record.url?scp=84992393639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992393639&partnerID=8YFLogxK

U2 - 10.3892/mmr.2016.5808

DO - 10.3892/mmr.2016.5808

M3 - Article

C2 - 27748813

AN - SCOPUS:84992393639

VL - 14

SP - 4622

EP - 4628

JO - Molecular Medicine Reports

JF - Molecular Medicine Reports

SN - 1791-2997

IS - 5

ER -